Hiroki Uehara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hiroki Uehara has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Marohito Nakata
Department of Cardiology, Urasoe General Hospital, Urasoe, Okinawa, Japan
3 shared publications Masami Abe
Department of Cardiology, Yuai Medical Center Hospital , Okinawa , Japan
1 shared publicationNaoko Yokota
Department of Cardiology, Urasoe General Hospital, Urasoe City, Okinawa, Japan
1 shared publicationShingo Hosogi
Department of Cardiology, Hosogi hospital , Kochi , Japan
1 shared publication- Shinichiro Ueda
Department of Clinical Research and Management, Graduate School of Medicine, University of Ryukyus, Japan; Department of Clinical Pharmacology, Faculty of Medicine, University of the Ryukyus, Japan
1 shared publication - Takashi Kajiya
Department of Cardiology, Tenyoukai Central Hospital, Kagoshima 892-0822, Japan
1 shared publication
Latest Publications
- Open Access
- 1 April 2025
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 15 (4) , 3298-3307
Comparison of diffusion-weighted whole-body magnetic resonance imaging and abdominal ultrasonography versus contrast-enhanced computed tomography in diagnosing acute focal bacterial nephritis: a retrospective cohort study
Background: Abdominal contrast-enhanced computed tomography (CT) is the gold standard for diagnosing acute focal bacterial nephritis (AFBN). However, contrast-enhanced CT is contraindicated for patients with contrast medium allergies, impaired renal function, pregnancy, metformin use, and thyroid disease. Diffusion-weighted whole-body magnetic resonance imaging (MRI) with background body signal suppression (DWIBS) is a safe imaging modality for such patients. Although DWIBS can quickly evaluate inflammation, its role in diagnosing AFBN remains unclear. Therefore, we aimed to compare imaging modalities for diagnosing AFBN and evaluate the efficacy of MRI DWIBS in patients receiving inpatient treatment. Methods: In this retrospective cohort study, we included individuals aged ≥18 years hospitalized for AFBN under the Diagnosis Procedure Combination system from January 1, 2013, to December 31, 2022. Exclusion criteria included imaging findings suggestive of AFBN. The primary outcome was the proportion of patients who underwent abdominal ultrasonography, contrast-enhanced CT, and MRI DWIBS and their respective diagnostic rates for AFBN. The secondary outcome was the accuracy of AFBN detection using abdominal ultrasonography and MRI DWIBS compared to that of the standard contrast-enhanced CT. Results: The study cohort included 123 patients, with an average age of 51±20.4 years; 107 (87.0%) were women. Abdominal ultrasonography was used in 74.0% (91/123) of the patients, yielding a diagnostic rate of 31.9% (29/91). Contrast-enhanced CT was used in 90.2% (111/123) of the patients, with a diagnostic rate of 100% (111/111). MRI DWIBS was used in 11.4% (14/123) of the patients, with a diagnostic rate of 85.7% (12/14). The accuracy of AFBN detection (correct response rate) was 26.6% (21/79) for abdominal ultrasonography and 75.0% (6/8) for MRI DWIBS, indicating that MRI DWIBS had a significantly higher accuracy rate than that of abdominal ultrasonography [Chi-square test, χ2(1) =7.96, P=0.0048]. Conclusions: MRI DWIBS demonstrated promising diagnostic accuracy for AFBN compared with abdominal ultrasonography, suggesting it could be a valuable diagnostic tool for this condition. Given its diagnostic accuracy, MRI DWIBS may be considered over abdominal ultrasonography in patients who are unable to undergo contrast-enhanced CT due to allergies or pregnancy. However, further prospective studies with larger sample sizes are necessary to validate these findings.
- 1 April 2025
- Published by AME Publishing Company in Quantitative Imaging in Medicine and Surgery
- Vol. 15 (4) , 3298-3307
Open AccessComparison of diffusion-weighted whole-body magnetic resonance imaging and abdominal ultrasonography versus contrast-enhanced computed tomography in diagnosing acute focal bacterial nephritis: a retrospective cohort study
Background: Abdominal contrast-enhanced computed tomography (CT) is the gold standard for diagnosing acute focal bacterial nephritis (AFBN). However, contrast-enhanced CT is contraindicated for patients with contrast medium allergies, impaired renal function, pregnancy, metformin use, and thyroid disease. Diffusion-weighted whole-body magnetic resonance imaging (MRI) with background body signal suppression (DWIBS) is a safe imaging modality for such patients. Although DWIBS can quickly evaluate inflammation, its role in diagnosing AFBN remains unclear. Therefore, we aimed to compare imaging modalities for diagnosing AFBN and evaluate the efficacy of MRI DWIBS in patients receiving inpatient treatment. Methods: In this retrospective cohort study, we included individuals aged ≥18 years hospitalized for AFBN under the Diagnosis Procedure Combination system from January 1, 2013, to December 31, 2022. Exclusion criteria included imaging findings suggestive of AFBN. The primary outcome was the proportion of patients who underwent abdominal ultrasonography, contrast-enhanced CT, and MRI DWIBS and their respective diagnostic rates for AFBN. The secondary outcome was the accuracy of AFBN detection using abdominal ultrasonography and MRI DWIBS compared to that of the standard contrast-enhanced CT. Results: The study cohort included 123 patients, with an average age of 51±20.4 years; 107 (87.0%) were women. Abdominal ultrasonography was used in 74.0% (91/123) of the patients, yielding a diagnostic rate of 31.9% (29/91). Contrast-enhanced CT was used in 90.2% (111/123) of the patients, with a diagnostic rate of 100% (111/111). MRI DWIBS was used in 11.4% (14/123) of the patients, with a diagnostic rate of 85.7% (12/14). The accuracy of AFBN detection (correct response rate) was 26.6% (21/79) for abdominal ultrasonography and 75.0% (6/8) for MRI DWIBS, indicating that MRI DWIBS had a significantly higher accuracy rate than that of abdominal ultrasonography [Chi-square test, χ2(1) =7.96, P=0.0048]. Conclusions: MRI DWIBS demonstrated promising diagnostic accuracy for AFBN compared with abdominal ultrasonography, suggesting it could be a valuable diagnostic tool for this condition. Given its diagnostic accuracy, MRI DWIBS may be considered over abdominal ultrasonography in patients who are unable to undergo contrast-enhanced CT due to allergies or pregnancy. However, further prospective studies with larger sample sizes are necessary to validate these findings.
- Open Access
- 6 July 2024
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 4 (4) , oeae055
Early and short-term use of proprotein convertase anti-subtilisin–kexin type 9 inhibitors on coronary plaque stability in acute coronary syndrome
Aims: Proprotein convertase anti-subtilisin–kexin type 9 inhibitors (PCSK9Is) improve plaque volume and composition and reduce major adverse coronary events in chronic coronary artery disease. We evaluated the effects of the short-term use of PCSK9Is on coronary plaque stability in patients with acute coronary syndrome (ACS) using optical coherence tomography (OCT). Methods and results: This is a multicentre, open-label randomized controlled trial. The enrolled 80 subjects met the inclusion criteria. Of these, 52 patients (age 60 ± 11 years, 38 men, 14 women) with ST-elevated ACS had undergone successful primary percutaneous coronary intervention with LDL-cholesterol (LDL-C) levels > 70 mg/dL while receiving high-intensity statins. Participants were randomly assigned to the PCSK9I group (evolocumab 420 mg for 3 months, n = 29) or the standard of care (SoC) group (n = 23). Optical coherence tomography was performed at baseline (BL) and 3 and 9 months after randomization to assess lipid-rich plaques in non-culprit lesions. The change in the minimum fibrous cap thickness (MFCT) from BL to 9 months was the primary endpoint. The percentage change in LDL-C levels from BL to 3 months was significantly greater in the PCSK9I group (−67.8 ± 21.5% in the PCSK9I group vs. −16.3 ± 21.8% in the SoC group; P < 0.0001), and the difference between the two groups disappeared from BL to 9 months (−20.0 ± 37.8% in the PCSK9I group vs. −6.7 ± 34.2% in the SoC group; P = 0.20). The changes in MFCT from BL to 9 months were significantly greater in the PCSK9I group, even after PCSK9I discontinuation {100 μm [interquartile range (IQR): 45–180 μm] vs. 50 μm [IQR: 0–110 μm]; P = 0.032}. Conclusion: Combination treatment with PCSK9Is and statins resulted in more marked plaque stabilization after ACS than SoC alone, and this effect persisted for 6 months after PCSK9I discontinuation. Registration: Adage-Joto study, UMIN ID No. 26516.
- 6 July 2024
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 4 (4) , oeae055
Open AccessEarly and short-term use of proprotein convertase anti-subtilisin–kexin type 9 inhibitors on coronary plaque stability in acute coronary syndrome
Aims: Proprotein convertase anti-subtilisin–kexin type 9 inhibitors (PCSK9Is) improve plaque volume and composition and reduce major adverse coronary events in chronic coronary artery disease. We evaluated the effects of the short-term use of PCSK9Is on coronary plaque stability in patients with acute coronary syndrome (ACS) using optical coherence tomography (OCT). Methods and results: This is a multicentre, open-label randomized controlled trial. The enrolled 80 subjects met the inclusion criteria. Of these, 52 patients (age 60 ± 11 years, 38 men, 14 women) with ST-elevated ACS had undergone successful primary percutaneous coronary intervention with LDL-cholesterol (LDL-C) levels > 70 mg/dL while receiving high-intensity statins. Participants were randomly assigned to the PCSK9I group (evolocumab 420 mg for 3 months, n = 29) or the standard of care (SoC) group (n = 23). Optical coherence tomography was performed at baseline (BL) and 3 and 9 months after randomization to assess lipid-rich plaques in non-culprit lesions. The change in the minimum fibrous cap thickness (MFCT) from BL to 9 months was the primary endpoint. The percentage change in LDL-C levels from BL to 3 months was significantly greater in the PCSK9I group (−67.8 ± 21.5% in the PCSK9I group vs. −16.3 ± 21.8% in the SoC group; P < 0.0001), and the difference between the two groups disappeared from BL to 9 months (−20.0 ± 37.8% in the PCSK9I group vs. −6.7 ± 34.2% in the SoC group; P = 0.20). The changes in MFCT from BL to 9 months were significantly greater in the PCSK9I group, even after PCSK9I discontinuation {100 μm [interquartile range (IQR): 45–180 μm] vs. 50 μm [IQR: 0–110 μm]; P = 0.032}. Conclusion: Combination treatment with PCSK9Is and statins resulted in more marked plaque stabilization after ACS than SoC alone, and this effect persisted for 6 months after PCSK9I discontinuation. Registration: Adage-Joto study, UMIN ID No. 26516.
- Open Access
- 23 December 2023
- Published by Elsevier in JACC: Case Reports
- Vol. 29 (3) , 102177
Bailout Strategy for Paclitaxel-Coated Nitinol Self-Expanding Stent Deployment Failure
- 23 December 2023
- Published by Elsevier in JACC: Case Reports
- Vol. 29 (3) , 102177
Open AccessBailout Strategy for Paclitaxel-Coated Nitinol Self-Expanding Stent Deployment Failure